Feature | September 28, 2010

Joint Agreement Reached for New Proton Beam Therapy System in Japan

Computer graphic of the proposed molecular-tracking radiotherapy system

September 28, 2010 — An agreement has been reached to begin joint development of a world-first novel proton beam therapy (PBT) system for cancer treatment under Japan’s FIRST program. Treatment will start in 2014.

Hokkaido University and Hitachi Ltd. will jointly develop a new type of PBT system by combining with the world-leading Japanese advanced medical technology. The proposed system was awarded a grant under the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program), a national project sponsored by the Japanese government. In line with the agreement, Hitachi will deliver this therapy system to Hokkaido University.

The FIRST Program is a major Japanese government initiative to incubate the world-leading science and technology to establish future Japanese technical backbone. Only 30 Core Researchers and Projects were awarded grants out of 565 applications throughout Japan in March 2010 by the Council for Science and Technology Policy. Hokkaido University’s Sustainable Development of Molecular-Tracking Radiotherapy System project, applied for by professor Hiroki Shirato, Department of Radiation Medicine, Graduate School of Medicine, was the only application accepted in the field of radiation therapy.

The proposed system is expected to advance radiation cancer therapy in Japan. Hokkaido University and Hitachi will combine real-time moving tumor tracking technology and spot scanning irradiation technology for the first time in the world to develop a compact and high-performance PBT system that can precisely target moving respiratory tumors. The new facility will be constructed adjacent to the Hokkaido University Hospital. It is scheduled to break ground in the fiscal year 2011 and be completed in March 2014. After completion, the new facility will start patient treatment as a part of Hokkaido University Hospital.

PBT is an advanced type of cancer radiotherapy. Protons, the atomic nucleus of hydrogen, are accelerated to high speed and their energy is concentrated on tumors. PBT enables patients to enjoy a normal life during treatment because almost no pain is associated with treatment and damage to the body’s functions or form is limited to the minimal level. PBT has thus attracted attention as a cutting-edge therapy for treating cancer while maintaining patients’ quality of life (QOL).

In addition, because dose is concentrated to a small spot, PBT can focus easily on cancers that do not move, like brain tumors. But treatment to tumors in areas such as the lungs and liver, which move in accordance with respiration, needs special care, and the combination of PBT with real-time tracking to target the tumor location is desirable.

Hokkaido University has focused on the development of technologies to concentrate irradiation dose to tumor locations for more than half a century. Professor Shirato has successfully developed real-time moving tumor tracking technology that automatically identifies the location of a gold marker inserted in the proximity of a moving tumor with X-ray fluoroscopic images and irradiates only when the tumor comes to the anticipated marker position. He has also developed the world’s first 4-D (four-dimensional) X-ray radiation therapy system employing this technology. These breakthroughs enable accurate targeting of X-ray radiation therapy to moving respiratory tumors by using real-time images.

In May 2008, Hitachi’s first spot-scanning irradiation technology that can concentrate irradiation dose to the tumor shape started patient treatment at the University of Texas M.D. Anderson Proton Therapy Center, one of the world’s largest hospitals specializing in cancer treatment. This marked the first clinical application of spot-scanning irradiation technology in a general hospital.

Hokkaido University and Hitachi entered into a comprehensive academia-industry collaboration agreement in April 2003 and since then have been conducting various joint researches. In the medical field, in particular, they have been jointly developing new molecular imaging technology for assessing and diagnosing the radio-resistance of cells that are critical in radiation therapy. This research trajectory followed selection of the technology in fiscal 2006 as a Future Drug Discovery and Medical Care Innovation Program as part of a major national project funded by the Special Coordination Fund for Promoting Science and Technology of the Ministry of Education, Culture, Sports, Science and Technology, which is expected to last for 10 years.

Under the FIRST Program, Hokkaido University and Hitachi will develop a PBT system that can accurately irradiate respiratory moving tumors by combining for the first time in the world the real-time moving tumor tracking technology accumulated by Hokkaido University in X-ray treatment and the spot-scanning irradiation technology Hitachi was first to deliver to a general hospital. Because protons boast superior dose distribution to X-rays, the combination of real-time moving tumor tracking technology and spot-scanning irradiation technology should yield more precise irradiation by drawing on the advantages of both technologies.

Hokkaido University and Hitachi will combine their respective technologies, knowledge and experience in the medical and engineering fields to contribute to cutting-edge radiation cancer therapy that maintains excellent QOL for patients through the development of this PBT system. Development work aims to popularize PBT worldwide by reducing the size of and simplifying accelerators and irradiation systems, to create a system that is internationally competitive.

Note: In parallel with development of a PBT system to create a Sustainable Development of Molecular-Tracking Radiotherapy System, Kyoto University professor Masahiro Hiraoka, who was a joint proposer of the project, plans to develop a tracking-image X-ray therapy system that tracks and irradiates tumors in the X-ray therapy field.

Overview of the PBT facility:
Planned construction site: Hokkaido University Campus, Kita 13, Nishi 6, Kita-ku, Sapporo
Site area: Approx. 2,000 m2
Planned building floor area: 946.94 m2
Planned total area: 2,850.48 m2
Structure and size: Four-floor, steel-reinforced concrete structure
Irradiation chamber: One rotating gantry treatment room

Overview of real-time moving tumor-tracking technology:
Real-time moving tumor-tracking technology inserts a 2 mm-diameter gold marker in the proximity of the tumor and uses a computed tomography (CT) system to identify the marker position in relation to the tumor core. Using an X-ray fluoroscopic system from two directions, the technology automatically pinpoints the gold marker position on a fluoroscopic image with pattern recognition technology and repeatedly calculates at intervals the spatial position. The targeted tumor will be irradiated only when the gold marker is located within several millimeters from the planned position.

As this operation is performed at high speed, it is possible for the first time in the world to irradiate the moving cancer cells with high accuracy. Compared with a conventional method to irradiate the whole area over which the tumor might migrate, this system reduces the irradiation volume to the level of one-half to one-quarter, thereby enabling a dramatic reduction of the irradiation of normal tissue.

Overview of spot-scanning irradiation technology
Spot-scanning irradiation technology does not scatter proton beams like conventional PBT method. Rather, it repeatedly turns the narrow beam on and off at high speed as it progressively changes location to irradiate the whole tumor volume. The protons can be targeted with high precision according to the shape of tumors, even those with complex shapes, eventually minimizing the impact on normal tissue.

For more information: hitachi.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...